Drugmakers Avoided Scaling AI in Manufacturing
A 2026 industry survey found that over 90% of pharmaceutical firms have not scaled AI in regulated production.
Updated on Oct. 6, 2026 in Artificial Intelligence
Live Poll
Do you trust artificial intelligence to manage sensitive production processes without human oversight?
According to the 2026 Horizons: Life Sciences report, more than 90% of drugmakers have not committed to scaling artificial intelligence in regulated manufacturing processes. The findings suggest that the vast majority of the industry remains years away from fully integrating AI into medicine production.
Why it matters
Manufacturing leaders face significant hurdles regarding AI model accuracy, validation standards, and transparency. These concerns make it difficult to provide the interpretable data required by regulatory agencies for compliance in highly sensitive medical production environments.
Only 9% of respondents are scaling AI for many or most regulated manufacturing applications, while 56% currently limit AI use to administrative workflows. Additionally, 74% of surveyed professionals stated they are years away from full AI adoption in regulated production.
The players
CRB
CRB is a provider of engineering, architecture, and construction solutions that tracks industry trends through its annual Horizons report series.
FDA
The Food and Drug Administration is the United States federal agency responsible for protecting public health by regulating the safety and efficacy of medical products.
Purolea Cosmetics Lab
Purolea Cosmetics Lab is a manufacturing firm that received a warning letter from federal regulators regarding its internal AI usage practices.
The details
While 45% of surveyed professionals utilize AI for drug discovery, high quality and accuracy standards continue to stall widespread implementation in manufacturing. In April 2026, the FDA highlighted these risks by issuing a warning letter to Purolea Cosmetics Lab, explicitly mandating human review of any AI-generated production outputs.
Timeline
The 2026 Horizons: Life Sciences report was published in 2026.
FDA inspectors issued a warning letter to Purolea Cosmetics Lab in April 2026.
Roughly 31% of surveyed professionals plan to implement AI in manufacturing within the next three years.
The Tech Race
The pharmaceutical industry is currently caught between the promise of high-speed automation and the rigid safety protocols of the FDA's Current Good Manufacturing Practice (CGMP) regulations. This gap marks a departure from other tech sectors where rapid deployment is prioritized over the extreme validation and accountability required for life-critical medicine production.
For the average consumer, this slow adoption rate means that most medications will continue to be produced using traditional, human-verified manufacturing methods for the foreseeable future. Patients and clinicians should expect high regulatory bars for any new AI-assisted production techniques to ensure product quality remains consistent.
The takeaway
The pharmaceutical industry remains cautious, prioritizing established validation standards over the rapid implementation of AI tools in manufacturing. Companies that successfully bridge the gap between model accuracy and regulatory transparency will likely set the benchmark for the next decade of production.
Further reading
For more on how emerging tools are reshaping sector operations, visit the /tech/artificial-intelligence/ section.
Source note: This article includes information reported by Pharma.
Live Poll
Do you trust artificial intelligence to manage sensitive production processes without human oversight?
